I’m in Menopause and on a Weight-Loss Jab — Should I Worry About My Bones?

Why are women in menopause turning to weight-loss jabs, and why does that combination matter for bone health?

Many women reach midlife facing two things at once: the metabolic shift of menopause, which often makes weight harder to lose, and the arrival of highly effective GLP-1 weight-loss jabs such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro). A 2026 review in Cureus noted that GLP-1 medications are associated with meaningful weight loss and reduced central fat in menopausal and postmenopausal women (GLP-1RAs for obesity and symptoms in menopause). So the appeal is real and well-founded.

The reason the combination deserves a closer look is that menopause and rapid weight loss each push bone density in the same direction — down — but through different routes. Understanding both lets you keep the weight-loss benefit while protecting the skeleton underneath it.

What does oestrogen loss actually do to your bones — and how fast does it happen?

Oestrogen acts as a brake on bone breakdown. When it falls at menopause, that brake comes off, and the cells that resorb bone (osteoclasts) become more active relative to the cells that build it. A 2025 review in Bone Research describes how hormonal disruption — including reduced oestrogen — is one of the core drivers of bone loss, alongside elevated parathyroid hormone, tilting the remodelling balance towards resorption (weight loss induced bone loss: mechanism of action).

On timing, the honest answer is that the years around the menopause transition are when this shift is most pronounced — bone loss tends to accelerate in early postmenopause and then ease. The practical point is that this is a window where the skeleton is already under pressure, which is exactly why adding a second stressor warrants attention.

Do weight-loss jabs directly damage bones, or is it the weight loss itself?

The best current evidence points to the weight loss, not direct drug toxicity. Bone is living tissue that adapts to the load placed on it, and several things happen during rapid weight loss at once. Bone Research sets out four mechanisms: mechanical unloading (a lighter body signals bone to remodel down), bone-marrow fat expansion that diverts stem cells away from bone-building, hormonal disruption, and nutritional gaps in vitamin D and calcium that can trigger secondary effects on bone (mechanism of action and clinical implications).

A 2025 review in Osteoporosis International concluded that GLP-1 medications produce a modest reduction in bone density and a shift in remodelling towards resorption that closely resembles ordinary calorie restriction (effects of GLP-1RAs on bone health). In other words, the jab appears to follow the well-worn path of any large, fast weight loss rather than acting as a bone poison — which matters, because it means much of the effect is preventable with the right support.

What does the research say about semaglutide, tirzepatide, and bone density loss?

The semaglutide evidence is the most solid. In a 2024 phase 2 randomised trial in eClinicalMedicine of 64 adults at increased fracture risk — mostly postmenopausal women — once-weekly semaglutide reduced bone mineral density at the total hip and lumbar spine compared with placebo over 52 weeks, and raised a marker of bone breakdown. The authors suggest this may be explained by the accompanying weight loss, which was about 6.8 kg greater than placebo (semaglutide versus placebo in adults with increased fracture risk). The Osteoporosis International review reports broadly similar magnitudes — reductions of roughly 2% at the spine and hip (effects on bone health).

For tirzepatide (Mounjaro), far less bone-specific data exists. It would be wrong to assume the semaglutide figures transfer directly; dedicated bone studies on tirzepatide are needed before any firm statement can be made. Evidence suggests the broad weight-loss-driven mechanism is likely to apply, but the specifics are not yet established.

One signal worth knowing about: in the large SELECT cardiovascular-outcomes trial, an exploratory analysis found more hip and pelvic fractures in women on semaglutide (1.0%) than placebo (0.2%) (reported in Osteoporosis International). Because SELECT was not designed to measure fractures, this is a signal warranting further study, not proof of cause — but it is a reason the research community is calling for dedicated bone-health studies within future trials.

Why does the combination of menopause and a GLP-1 jab create a compounded risk — and how big is it?

Mechanistically, you have two independent downward pressures on bone arriving together. Menopause has already removed oestrogen's restraint on bone breakdown, and a GLP-1 jab adds a second, weight-loss-driven stimulus to lose bone. The 2026 Cureus menopause review reflects this uncertainty directly: bone outcomes across GLP-1 drugs were genuinely mixed — some agents were linked to reduced fracture risk, others showed no benefit — and it concluded that further research is needed, with many studies small, short or based on animal models (GLP-1RAs in menopause).

As for how big the combined risk is, the honest answer is that no study has quantified menopause plus a jab as a single figure. What the literature does show is that postmenopausal bone loss during weight reduction can be difficult to reverse. A Menopause study following postmenopausal women found significant bone loss at the hip after about 10% weight loss, with those who kept the weight off continuing to lose bone over two years (does bone loss begin after weight loss ends?). A separate study in Obesity found that even when women regained weight, the bone density lost during weight reduction was largely not restored (weight regain does not restore weight loss-induced bone loss). The takeaway is not a scary number — it's that bone lost in this window may not come back, so protecting it while losing weight matters more than hoping to recover it later.

Can you protect your bones while still losing weight on a jab?

Yes — and the single most powerful protective factor in the research is exercise. In a 2024 JAMA Network Open secondary analysis of 195 adults, the GLP-1 medication (liraglutide) alone reduced bone density at the hip and spine, whereas adding exercise preserved it — and the combination group even increased forearm bone density, despite losing nearly 17 kg (bone health after exercise, GLP-1 treatment, or combination). (That trial used liraglutide specifically, so the precise figures apply to that drug, but the principle — load your bones while you lose weight — is broadly relevant.)

In practice, that means:

• Resistance training (weights, bands, bodyweight) two to three times a week to load muscle and bone.
• Weight-bearing activity — brisk walking, stairs, dancing.
• Adequate protein to defend lean muscle, which in turn supports bone.
• Calcium and vitamin D sufficiency, especially as appetite falls on a jab.

For some postmenopausal women, HRT may also form part of the picture. The 2024 UK osteoporosis guideline (NOGG) introduced HRT as a first-line option for younger postmenopausal women (age ≤60) at high fracture risk with low risk of other complications (UK clinical guideline for osteoporosis). Whether that's right for you is a conversation for your GP, ideally informed by knowing your actual bone status.

How do you know what is actually happening to your bones — and what can you do about it in the UK?

You can't manage what you can't measure — and right now most women on weight-loss jabs are losing bone silently. There is no routine NHS bone-monitoring programme for people on these medications, so unless you check, you simply won't know whether your density is holding or falling. The UK guideline recommends FRAX-based fracture-risk assessment for any postmenopausal woman with a clinical risk factor (NOGG guideline) — and being on a jab during menopause is a reasonable prompt to have that conversation.

A baseline scan answers the only question that really matters: is my bone density changing, and do I need to act? Because the changes are gradual, catching them early is exactly when prevention works best.

REMS (Radiofrequency Echographic Multi Spectrometry) is radiation-free, so it can be repeated safely across a one- or two-year course of treatment to track change over time — useful when you want to monitor rather than scan once. It offers an accessible baseline rather than replacing specialist diagnostic pathways.

You can book a radiation-free bone health assessment, read more about our bone health assessment and how REMS measures bone density, or see where we screen across the UK.

---

This article is part of our menopause and bone health series. If you're focused on the medication side, see our companion guide on Ozempic, weight-loss injections and bone loss. Always discuss your individual fracture risk and any HRT decision with your GP.